Sleep neurotech is moving beyond proxy tracking toward systems that read, shape, and adapt to sleep. The field now spans EEG and fNIRS wearables, adaptive audio and light, electrical and peripheral stimulation, and clinical devices for insomnia, sleep apnea, restless legs syndrome, and diagnostics.

Japan has deep neuroscience infrastructure, long-running public programs, and an emerging neurotechnology startup layer. Its position is distinct from larger U.S. and Chinese markets, with strength in research, robotics, manufacturing, and governance, but a less defined path to clinical translation and global scale.

China’s neurotech market is no longer a distant subplot. With state-backed BCI plans, new standards, major funding rounds, and its first approved implantable BCI, a once-fragmented field is becoming an organised national push across implants, ultrasound, EEG, neuromodulation, and restoration.

Behind closed labs, Big Tech is moving deeper into brain science. From Meta’s brain models to OpenAI’s BCI bet, neurotechnology is becoming a new interface layer for AI, advertising, and attention. The technology is quickly falling into the hands of the wealthy, but should they control it?

Neurotech companies are learning that scientific progress is only half the battle. From Precision’s fast 510(k) clearance to QuantalX’s De Novo category and Flow’s PMA path, the field is entering a phase where regulatory strategy may decide who reaches patients first.

After rockets, AI, and social media empires, billionaires are now chasing the brain. From Musk’s Neuralink to Altman’s Merge Labs and Zuckerberg’s neural wristband, neurotech has become the next frontier where capital, ego, patient need, and public trust collide.